Abstract
Importance Whether earlier onset of puberty is associated with higher cardiovascular risk in early adulthood is not well understood.
Objective To examine the association between puberty timing and markers of cardiovascular structure and function at age 25 years.
Design Prospective birth cohort study.
Setting The Southwest region of England.
Participants Participants in the Avon Longitudinal Study of Parents and Children (ALSPAC), born between April 1, 1991, and December 31, 1992.
Exposure Age at peak height velocity (aPHV), an objective and validated growth-based measure of puberty onset.
Main Outcomes and Measures Cardiovascular structure and function at age 25 years: carotid intima-media thickness (CIMT), left ventricular mass index (LVMI) and relative wall thickness (RWT), pulse wave velocity (PWV) and systolic blood pressure (SBP). Multiple imputation was used to impute missing data on covariates and outcomes. Linear regression was used to examine the association between aPHV and each measure of cardiac structure and function, adjusting for maternal age, gestational age, household social class, maternal education, mother’s partner’s education, breastfeeding, parity, birthweight, maternal body mass index, maternal marital status, maternal prenatal smoking status, and height and fat mass at age 9. All analyses were stratified by sex.
Results A total of 2752-4571 participants were included in the imputed analyses. A one-year older aPHV was not strongly associated with markers of cardiac structure and function in males and females at 25 years and most results spanned the null value. In adjusted analyses a one-year older aPHV was associated with 0.003mm (95% Confidence Interval (CI): 0.00001, 0.006) and 0.0008mm (95% CI: −0.002, 0.003) higher CIMT; 0.02m/s (95% CI: −0.05, 0.09) and 0.02m/s (95% CI: −0.04, 0.09) higher PWV; and 0.003mmHg (95% CI: −0.60, 0.60) and 0.13mmHg (95% CI: −0.44, 0.70) higher SBP, among males and females respectively. A one-year older aPHV was associated with −0.55g/m2.7 (95% CI: −0.03, −1.08) and −0.89g/m2.7 (95% CI: −0.45, −1.34) lower LVMI and −0.001 (95% CI: −0.006, 0.002) and −0.002 (95% CI: −0.006, 0.002) lower RWT among males and females.
Conclusions and Relevance Earlier puberty is unlikely to have a major impact on pre-clinical cardiovascular risk in early adulthood.
Question Is puberty timing associated with cardiovascular structure and function at age 25 years?
Findings Adjusted estimates from this prospective birth cohort study suggest no strong evidence of association between age at puberty (measured using age at peak height velocity) and carotid intima-media thickness (CIMT), left ventricular mass index (LVMI), and relative wall thickness (RWT), pulse wave velocity (PWV), and systolic blood pressure (SBP) at age 25 years among males and females, with results spanning the null in all but LVMI.
Meaning Earlier puberty is unlikely to have a major impact on pre-clinical cardiovascular risk in early adulthood.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The UK Medical Research Council and Wellcome (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. A comprehensive list of grants funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf); This research was specifically funded by Wellcome Trust and MRC (core) (Grant refs: 076467/Z/05/Z, 086676/Z/08/Z), and British Heart Foundation (Grant refs: CS/15/6/31468, PG106/145, RG/10/004/28240). GMM is supported by Health Research Board (HRB), Ireland, (SDAP2019/ 6359). LMOK is supported by a HRB, Ireland Emerging Investigator Award (EIA-FA-2019-007 SCaRLeT) and a UK Medical Research Council Population Health Scientist fellowship (MR/M014509/1). LDH and AF are supported by Career Development Awards from the UK Medical Research Council (grants MR/M020894/1 and MR/M009351/1, respectively). AH received support from the Wellcome Trust (086676/7/08/Z) and the British Heart Foundation (PG/06/145 & CS/15/6/31468) and works in a unit that receives support from the UK Medical Research Council (Programme Code MC_UU_12019/1). These funding sources had no role in the design and conduct of this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the ALSPAC study was obtained from the ALSPAC Law and Ethics Committee and Local Research Ethics Committees. Informed consent for the use of data collected via questionnaires and clinics was obtained from participants following the recommendations of the ALSPAC Law and Ethics Committee at the time.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding The UK Medical Research Council and Wellcome (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. A comprehensive list of grants funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf); This research was specifically funded by Wellcome Trust and MRC (core) (Grant refs: 076467/Z/05/Z, 086676/Z/08/Z), and British Heart Foundation (Grant refs: CS/15/6/31468, PG106/145, RG/10/004/28240). GMM is supported by Health Research Board (HRB), Ireland, (SDAP2019/ 6359). LMOK is supported by a HRB, Ireland Emerging Investigator Award (EIA-FA-2019-007 SCaRLeT) and a UK Medical Research Council Population Health Scientist fellowship (MR/M014509/1). LDH and AF are supported by Career Development Awards from the UK Medical Research Council (grants MR/M020894/1 and MR/M009351/1, respectively). AH received support from the Wellcome Trust (086676/7/08/Z) and the British Heart Foundation (PG/06/145 & CS/15/6/31468) and works in a unit that receives support from the UK Medical Research Council (Programme Code MC_UU_12019/1). These funding sources had no role in the design and conduct of this study. This publication is the work of the authors and GMM will serve as guarantor for the contents of this paper.
Disclosures: None of the authors have any conflicts of interest to declare.
Data Availability
The study website contains details of all the data that is available through a fully searchable data dictionary and variable search tool: http://www.bristol.ac.uk/alspac/researchers/our-data/
